Specialists in Israel determine lung cancer treatment plans through multidisciplinary tumor boards where surgeons, oncologists, and radiologists collaborate. They use genomic profiling and T-cell sequencing to identify specific mutations, ensuring every patient receives a personalized therapy roadmap based on their unique biology.
- Molecular tumor boards. Teams review genomic data to select targeted therapies for specific genetic mutations.
- Customized protocols. Dr. Ofer Merimsky at Sourasky develops unique protocols combining chemo-radiotherapy before surgery.
- Immunotherapy research. Dr. Jair Bar leads studies on immunotherapy resistance to optimize drug selection.
- Translational oncology. Dr. Ari Raphael at Sourasky uses T-cell repertoire sequencing for advanced innovation.
Bookimed Expert Insight: Israeli lung cancer specialists often hold dual certifications in oncology and radiotherapy. For example, Dr. Raphael Pfeffer at Assuta and Dr. Jair Bar at Sheba are board-certified in both. This dual expertise allows one doctor to manage both radiation and drug therapy. This integration usually leads to faster transitions between treatment phases compared to separate departments.
Patient Consensus: Patients often mention how quickly doctors move from the first consultation to a full treatment plan. Many were surprised that a single specialist could coordinate both their chemotherapy and radiation sessions efficiently.
